Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
DISHMAN PHARMA | GSK PHARMA | DISHMAN PHARMA/ GSK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | -79.1 | - | View Chart |
P/BV | x | 3.3 | 11.8 | 28.4% | View Chart |
Dividend Yield | % | 0.7 | 1.3 | 49.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
GSK PHARMA Mar-19 |
DISHMAN PHARMA/ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 3,595 | 10.4% | |
Low | Rs | 129 | 1,253 | 10.3% | |
Sales per share (Unadj.) | Rs | 197.8 | 184.7 | 107.1% | |
Earnings per share (Unadj.) | Rs | 21.2 | 26.3 | 80.7% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 29.2 | 119.1% | |
Dividends per share (Unadj.) | Rs | 2.00 | 20.00 | 10.0% | |
Dividend yield (eoy) | % | 0.8 | 0.8 | 96.3% | |
Book value per share (Unadj.) | Rs | 179.9 | 126.3 | 142.4% | |
Shares outstanding (eoy) | m | 80.69 | 169.40 | 47.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 1.3 | 13.1 | 9.7% | |
Avg P/E ratio | x | 11.9 | 92.2 | 12.9% | |
P/CF ratio (eoy) | x | 7.2 | 83.1 | 8.7% | |
Price / Book Value ratio | x | 1.4 | 19.2 | 7.3% | |
Dividend payout | % | 9.4 | 76.1 | 12.4% | |
Avg Mkt Cap | Rs m | 20,306 | 410,626 | 4.9% | |
No. of employees | `000 | 0.8 | 5.0 | 16.7% | |
Total wages/salary | Rs m | 5,355 | 5,372 | 99.7% | |
Avg. sales/employee | Rs Th | 19,252.7 | 6,306.7 | 305.3% | |
Avg. wages/employee | Rs Th | 6,459.5 | 1,083.1 | 596.4% | |
Avg. net profit/employee | Rs Th | 2,064.1 | 898.0 | 229.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 31,281 | 51.0% | |
Other income | Rs m | 265 | 1,023 | 25.9% | |
Total revenues | Rs m | 16,226 | 32,304 | 50.2% | |
Gross profit | Rs m | 4,103 | 6,009 | 68.3% | |
Depreciation | Rs m | 1,091 | 486 | 224.4% | |
Interest | Rs m | 944 | 6 | 15,740.0% | |
Profit before tax | Rs m | 2,334 | 6,540 | 35.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 287 | 0.0% | |
Tax | Rs m | 624 | 2,373 | 26.3% | |
Profit after tax | Rs m | 1,711 | 4,454 | 38.4% | |
Gross profit margin | % | 25.7 | 19.2 | 133.8% | |
Effective tax rate | % | 26.7 | 36.3 | 73.6% | |
Net profit margin | % | 10.7 | 14.2 | 75.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 20,061 | 54.9% | |
Current liabilities | Rs m | 9,517 | 14,543 | 65.4% | |
Net working cap to sales | % | 9.4 | 17.6 | 53.3% | |
Current ratio | x | 1.2 | 1.4 | 83.9% | |
Inventory Days | Days | 110 | 57 | 194.6% | |
Debtors Days | Days | 35 | 14 | 247.8% | |
Net fixed assets | Rs m | 16,304 | 14,343 | 113.7% | |
Share capital | Rs m | 161 | 1,694 | 9.5% | |
"Free" reserves | Rs m | 12,907 | 19,704 | 65.5% | |
Net worth | Rs m | 14,516 | 21,398 | 67.8% | |
Long term debt | Rs m | 4,189 | 2 | 209,470.0% | |
Total assets | Rs m | 29,805 | 39,113 | 76.2% | |
Interest coverage | x | 3.5 | 1,091.0 | 0.3% | |
Debt to equity ratio | x | 0.3 | 0 | 308,794.0% | |
Sales to assets ratio | x | 0.5 | 0.8 | 67.0% | |
Return on assets | % | 8.9 | 11.4 | 78.1% | |
Return on equity | % | 11.8 | 20.8 | 56.6% | |
Return on capital | % | 17.5 | 31.9 | 54.9% | |
Exports to sales | % | 24.8 | 0 | - | |
Imports to sales | % | 3.7 | 0 | - | |
Exports (fob) | Rs m | 3,956 | NA | - | |
Imports (cif) | Rs m | 596 | NA | - | |
Fx inflow | Rs m | 4,952 | 534 | 927.2% | |
Fx outflow | Rs m | 697 | 7,091 | 9.8% | |
Net fx | Rs m | 4,255 | -6,557 | -64.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 3,994 | 69.8% | |
From Investments | Rs m | -1,529 | -1,433 | 106.7% | |
From Financial Activity | Rs m | -941 | -3,584 | 26.3% | |
Net Cashflow | Rs m | 316 | -1,023 | -30.9% |
Indian Promoters | % | 61.4 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 50.7 | - | |
Indian inst/Mut Fund | % | 3.7 | 10.2 | 36.3% | |
FIIs | % | 12.7 | 23.8 | 53.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 15.4 | 143.5% | |
Shareholders | 46,261 | 102,036 | 45.3% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: PIRAMAL ENTERPRISES ABBOTT INDIA PANACEA BIOTECH DR. REDDYS LAB NOVARTIS
Compare DISHMAN PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More